Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study

Trial Profile

Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 25 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 18FFP-R01-MG-F2 (Primary)
  • Indications Pancreatic cancer
  • Focus Diagnostic use; First in man; Pharmacokinetics

Most Recent Events

  • 20 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 08 Apr 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
  • 08 Apr 2022 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top